The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Open accessAbstract
Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is associated with enhanced survival and antigen-specific T cell responses compared with adjuvant treatment1; however, optimal regimens have not been defined. Here we report results from a randomized phase 2 study of neoadjuvant nivolumab versus combined ipilimumab with nivolumab in 23 patients with high-risk resectable melanoma (NCT02519322). RECIST overall response rates (ORR), pathologic complete response rates (pCR), treatment-related adverse events (trAEs) and immune correlates of response were assessed. Treatment with combined ipilimumab and nivolumab yielded high response rates (RECIST ORR 73%, pCR 45%) but substantial toxicity (73% grade 3 trAEs), whereas treatment with nivolumab monotherapy yielded modest responses (ORR 25%, pCR 25%) and low toxicity (8% grade 3 trAEs). Immune correlates of response were identified, demonstrating higher lymphoid infiltrates in responders to both therapies and a more clonal and diverse T cell infiltrate in responders to nivolumab monotherapy. These results describe the feasibility of neoadjuvant immune checkpoint blockade in melanoma and emphasize the need for additional studies to optimize treatment regimens and to validate putative biomarkers. Neoadjuvant combination treatment with nivolumab and ipilimumab in patients with high-risk melanoma results in higher response rates than nivolumab monotherapy and warrants future optimization of dosing regimens to preserve efficacy while limiting toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“analyses of samples derived from patients with melanoma who received neoadjuvant ICIs112,113 have revealed the presence of the three primary patterns of T cell infiltration identified in solid tumours.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [113]
Experimental — accuracy not yet measuredIn the citing paper
“Studies in melanoma using higher dosages of ipilimumab reported enhanced immune infiltration in responding tumors17.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [17]
In the citing paper
“Amaria and colleagues17 demonstrated that a more clonal T-cell repertoire at baseline correlated with response to neoadjuvant ICI therapy in patients with melanoma, with further expansion of the pre-existing high-frequency clones with treatment.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [17]
In the citing paper
“Key roles of TGF-β1 in suppressing the adaptive immune system are apparent from the lymphoproliferative autoimmune phenotype of Tgfb1−/− mice197–199, and similar phenotypes following selective ablation of TGF-β signaling components within CD4+ and CD8+ T cells200.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [198]
In the citing paper
“Clinical trials with ICT in the neoadjuvant setting have now demonstrated clinical benefit in multiple tumor types, including melanoma (173, 174), Merkel cell carcinoma (175), NSCLC (176), MMRdeficient colorectal cancer (177), urothelial carcinoma (21, 178), and breast cancer (179-181).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [173]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,508
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,055
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
Gloor, S., Jensen, K. O., Breitenstein, S., Binkert, C. A., Angst, E., & Hetzer, F. H. (2017) · Case Reports in Gastroenterology · doi:10.1159/000463378 · Cited by 5,370
Research works printed but not linked: 1
- Edge, S. B. AJCC Cancer Staging Manual 7th edn (Springer, New York, 2010).
Cited by
Sorted by citations
Items 201–300 of 838
Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy
Benítez, J. C., Remón, J., & Besse, B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3255 · Cited by 53
Albittar, A. A., Alhalabi, O., & Oliva, I. C. G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_3 · Cited by 57
Immune checkpoint inhibitors for the treatment of melanoma
Sabbatino, F., Liguori, L., Pepe, S., & Ferrone, S. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2038132 · Cited by 56
Kaptein, P., Jacoberger-Foissac, C., Dimitriadis, P., Voabil, P., de Bruijn, M. J. W., Brokamp, S., Reijers, I. L. M., Versluis, J. M., Nallan, G., Triscott, H., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj9779 · Cited by 55
Zhu, Y., Jin, L., Chen, J., Su, M., Sun, T., & Yang, X. (2023) · Advanced Materials · doi:10.1002/adma.202309667 · Cited by 54
Torphy, R. J., Schulick, R. D., & Zhu, Y. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23179 · Cited by 54
Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease
Mittendorf, E. A., Burgers, F. H., Haanen, J. B. A. G., & Cascone, T. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349411 · Cited by 54
Lian, B., Li, Z., Wu, N., Li, M., Chen, X., Zheng, H. Y., Gao, M., Wang, D., Sheng, X., Tian, H., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.793 · Cited by 54
Combination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer – a brief update
Park, J., & Skålhegg, B. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680838 · Cited by 66
Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy
Trojaniello, C., Luke, J. J., & Ascierto, P. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670726 · Cited by 53
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
Lucas, M. W., Versluis, J. M., Rozeman, E. A., & Blank, C. U. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00760-3 · Cited by 50
Perez, B. A., Kim, S., Wang, M.-H., Karimi, A. M., Powell, C. D., Li, J., Dilling, T. J., Chiappori, A., Latifi, K., Rose, T. A., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.09.031 · Cited by 49
Xie, Y., Lin, J., Zhang, N., Wang, X., Wang, P., Peng, S., Li, J., Wu, Y., Huang, Y., Zhuang, Z., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7071 · Cited by 49
Marie, P. K., Haymaker, C., Parra, E. R., Kim, Y. U., Lazcano, R., Gite, S., Lorenzini, D., Wistuba, I. I., Tidwell, R. S. S., Song, X., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0163 · Cited by 49
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Sanmamed, M. F., Berraondo, P., Rodriguez-Ruiz, M. E., & Melero, I. (2022) · Nature Cancer · doi:10.1038/s43018-022-00401-1 · Cited by 50
Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
Petrova, V., Arkhypov, I., Weber, R., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072367 · Cited by 50
Self-citationBlankenstein, S. A., Rohaan, M. W., Klop, W. M. C., van der Hiel, B., van de Wiel, B. A., Lahaye, M. J., Adriaansz, S., Sikorska, K., van Tinteren, H., Sari, A., et al. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000004893 · Cited by 48
The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma
Albrecht, L. J., Livingstone, E., Zimmer, L., & Schadendorf, D. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01406-4 · Cited by 49
Immunocytes in the tumor microenvironment: recent updates and interconnections
Yu, J., Fu, L., Wu, R., Che, L., Liu, G., Ran, Q., Xia, Z., Liang, X., & Zhao, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1517959 · Cited by 52
Shakya, R., Nguyen, T. H., Waterhouse, N. J., & Khanna, R. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1183 · Cited by 46
Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions
Ser, M. H., Webb, M., Sener, U. T., & Campian, J. L. (2023) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-23-34 · Cited by 51
Long, G. V., Carlino, M. S., Au‐Yeung, G., Spillane, A. J., Shannon, K. F., Gyorki, D. E., Hsiao, E., Kapoor, R., Thompson, J., Batula, I., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03077-5 · Cited by 48
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types
Awada, G., Cascone, T., van der Heijden, M. S., Blank, C. U., Kok, M., & Chalabi, M. (2025) · Nature Cancer · doi:10.1038/s43018-025-00990-7 · Cited by 51
Radiotherapy as a Backbone for Novel Concepts in Cancer Immunotherapy
Kabiljo, J., Harpain, F., Carotta, S., & Bergmann, M. M. (2019) · Cancers · doi:10.3390/cancers12010079 · Cited by 48
van Akkooi, A. C. J., Hieken, T. J., Burton, E. M., Ariyan, C. E., Ascierto, P. A., Asero, S. V. M. A., Blank, C. U., Block, M. S., Boland, G. M., Caracò, C., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11236-y · Cited by 47
Self-citationHong, W. X., Sagiv-Barfi, I., Czerwinski, D. K., Sallets, A., & Levy, R. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-1382 · Cited by 43
Zhu, P., #x2019, #x2019, Lu, H., Wang, M., Chen, K., Chen, Z., & Yang, L. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0491 · Cited by 44
Combination Therapy as a Promising Way to Fight Oral Cancer
Silva, J. P. N., Pinto, B. F., Monteiro, L. S., Silva, P. M. A., & Bousbaa, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061653 · Cited by 48
Li, Z., Liu, J., Zhang, B., Yue, J., Shi, X., Cui, K., Liu, Z., Chang, Z., Sun, Z., Li, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47420-3 · Cited by 48
Novel adjuvant options for cutaneous melanoma
Dimitriou, F., Long, G. V., & Menzies, A. M. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.198 · Cited by 44
Pan, M., & Li, B. (2022) · eLife · doi:10.7554/elife.81952 · Cited by 42
Labadie, B. W., Liu, P., Bao, R., Crist, M., Fernandes, R., Ferreira, L., Graupner, S., Poklepovic, A. S., Durán, I., Vareki, S. M., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-02144-7 · Cited by 43
Molecular imaging to support cancer immunotherapy
van de Donk, P. P., Oosting, S. F., Knapen, D. G., van der Wekken, A. J., Brouwers, A. H., Hooge, M. N. L., de Groot, D. J., & de Vries, E. G. E. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004949 · Cited by 43
B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors
Flippot, R., Teixeira, M., Rey-Cárdenas, M., Carril-Ajuria, L., Rainho, L., Naoun, N., Jouniaux, J.-M., Boselli, L., Naigeon, M., Danlos, F., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008636 · Cited by 47
Immunologic and immunogenomic aspects of tumor progression
Ladányi, A., & Tímár, J. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.011 · Cited by 42
Neoadjuvant immunotherapy for melanoma
Lee, A. Y., & Brady, M. S. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.26229 · Cited by 43
Immunotherapy use outside clinical trial populations: never say never?
Rzeniewicz, K., Larkin, J., Menzies, A. M., & Turajlic, S. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.199 · Cited by 42
van Dorp, J., & van der Heijden, M. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1235884 · Cited by 42
Oliva, I. C. G., & Alqusairi, R. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02505-2_2 · Cited by 41
Neoadjuvant immunotherapy of locoregionally advanced solid tumors
Tarhini, A. A., Eads, J. R., Moore, K. N., Tatard-Leitman, V. M., Wright, J., Forde, P. M., & Ferris, R. L. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005036 · Cited by 40
A variety of ‘exhausted’ T cells in the tumor microenvironment
Nagasaki, J., & Togashi, Y. (2022) · International Immunology · doi:10.1093/intimm/dxac013 · Cited by 43
Relecom, A., Merhi, M., Inchakalody, V. P., Shahab Uddin, M. S., Rinchai, D., Bedognetti, D., & Dermime, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01872-3 · Cited by 41
Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity
Burton, E. M., & Tawbi, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0257 · Cited by 40
Self-citationApplication of T cell receptor (TCR) repertoire analysis for the advancement of cancer immunotherapy
Joshi, K., Milighetti, M., & Chain, B. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.07.006 · Cited by 44
Sarsembayeva, A., Kienzl, M., Gruden, E., Ristić, D., Maitz, K. S., Valadez-Cosmes, P., Santiso, A., Hasenoehrl, C., Brčić, L., Lindenmann, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997115 · Cited by 39
Li, S., Xu, Q., Dai, X., Zhang, X., Huang, M., Huang, K., Shi, D., Wang, J., & Liu, L. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13143-w · Cited by 39
New paradigm for stage III melanoma: from surgery to adjuvant treatment
Ascierto, P. A., Borgognoni, L., Botti, G., Guida, M., Marchetti, P., D, S. M. M., Muto, P., Palmieri, G., Patuzzo, R., Quaglino, P., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2012-2 · Cited by 41
Role of Surgery for Metastatic Melanoma
Enomoto, L. M., Levine, E. A., Shen, P., & Votanopoulos, K. I. (2019) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.09.011 · Cited by 41
Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma
Monti, M., Consoli, F., Vescovi, R., Bugatti, M., & Vermi, W. (2020) · Cells · doi:10.3390/cells9020417 · Cited by 41
Cell Atlas technologies and insights into tissue architecture
Wilbrey-Clark, A., Roberts, K., & Teichmann, S. A. (2020) · Biochemical Journal · doi:10.1042/bcj20190341 · Cited by 39
Dickhoff, C., Senan, S., Schneiders, F. L., Veltman, J. D., Hashemi, S. M. S., Daniels, J. M. A., Fransen, M. F., Heineman, D. J., Radonic, T., van de Ven, P. M., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07263-9 · Cited by 39
Hu, X., Zhu, H., Zhang, X., He, X., & Xu, X. (2021) · Cancer Medicine · doi:10.1002/cam4.4203 · Cited by 41
Adjuvant Therapy for Melanoma: Past, Current, and Future Developments
Testori, A., Chiellino, S., & van Akkooi, A. C. J. (2020) · Cancers · doi:10.3390/cancers12071994 · Cited by 39
Herck, Y. V., Antoranz, A., Andhari, M. D., Milli, G., Bechter, O. E., Smet, F. D., & Bosisio, F. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.636681 · Cited by 40
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B. J., Fong, L. H., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0235-z · Cited by 38
The potential and promise for clinical application of adoptive T cell therapy in cancer
Li, Y., Zheng, Y., Liu, T., Liao, C., Shen, G., & He, Z. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05206-7 · Cited by 41
Kulasinghe, A., Taheri, T., O'Byrne, K. J., Hughes, B. G. M., Kenny, L., & Punyadeera, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.607349 · Cited by 37
Poznanski, S. M., Ritchie, T. M., Fan, I. Y., El‐Sayes, A., Portillo, A. L., Ben-Avi, R., Rojas, E. A. P., Chew, M. V., Shargall, Y., & Ashkar, A. A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001933 · Cited by 37
Wang, S., Yuan, P., Mao, B., Li, N., Ying, J., Tao, X., Tang, W., Zhang, L., Geng, X., Zhang, F., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-021-00244-6 · Cited by 38
Neoadjuvant Immunotherapy in Melanoma: The Paradigm Shift
Hieken, T. J., Kreidieh, F., Aedo-Lopez, V., Block, M. S., McArthur, G. A., & Amaria, R. N. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390614 · Cited by 37
Self-citationRohaan, M. W., Stahlie, E. H. A., Franke, V., Zijlker, L. P., Wilgenhof, S., van der Noort, V., van Akkooi, A. C. J., & Haanen, J. B. A. G. (2022) · BMC Cancer · doi:10.1186/s12885-022-09896-4 · Cited by 36
Sharon, C. E., Tortorello, G. N., Ma, K. L., Huang, A. C., Xu, X., Giles, L. R., McGettigan, S., Kreider, K., Schuchter, L. M., Mathew, A. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.06.006 · Cited by 36
Is earlier better for melanoma checkpoint blockade?
Robert, C. (2018) · Nature Medicine · doi:10.1038/s41591-018-0250-0 · Cited by 37
Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials
Witt, R. G., Erstad, D. J., & Wargo, J. A. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221083052 · Cited by 35
Self-citationClassic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer
Rubatto, M., Sciamarrelli, N., Borriello, S., Pala, V., Mastorino, L., Tonella, L., Ribero, S., & Quaglino, P. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.959289 · Cited by 36
Liu, Y., Altreuter, J., Bodapati, S., Cristea, S., Wong, C. J., Wu, C. J., & Michor, F. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100444 · Cited by 39
neoepiscope improves neoepitope prediction with multivariant phasing
Wood, M. A., Nguyen, A., Struck, A. J., Ellrott, K., Nellore, A., & Thompson, R. F. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz653 · Cited by 35
The adjuvant treatment revolution for high-risk melanoma patients
Spagnolo, F., Boutros, A., Tanda, E. T., & Queirolo, P. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.024 · Cited by 35
Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma
Galvani, E., Mundra, P. A., Valpione, S., García-Martínez, P. L., Smith, M., Greenall, J., Thakur, R., Helmink, B. A., Andrews, M. C., Boon, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14632-2 · Cited by 36
Self-citationTargeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect
Bai, X. L., & Flaherty, K. T. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19394 · Cited by 38
Gastman, B., Agarwal, P. K., Berger, A., Boland, G. M., Broderick, S., Butterfield, L. H., Byrd, D. R., Fecci, P. E., Ferris, R. L., Fong, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001583 · Cited by 39
MATISSE: a method for improved single cell segmentation in imaging mass cytometry
Baars, M. J. D., Sinha, N., Amini, M., Pieterman-Bos, A., van Dam, S., Ganpat, M. M. P., Laclé, M. M., Oldenburg, B., & Vercoulen, Y. (2021) · BMC Biology · doi:10.1186/s12915-021-01043-y · Cited by 35
The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges
Stege, H. M., Haist, M., Nikfarjam, U., Schultheis, M., Heinz, J., Pemler, S., Loquai, C., & Grabbe, S. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00840-3 · Cited by 35
van Akkooi, A. C. J., Blank, C. U., & Eggermont, A. M. M. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.01.004 · Cited by 36
Detection and quantitative analysis of tumor-associated tertiary lymphoid structures
Yang, M., Che, Y., Li, K., Fang, Z., Li, S., Wang, M., Zhang, Y., Zhu, X., Luo, L., Wu, C. K., et al. (2023) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200605 · Cited by 34
Immune checkpoint inhibitors in metastatic melanoma therapy (Review)
Shah, V., Panchal, V. S., Shah, A., Vyas, B., Agrawal, S. P., & Bharadwaj, S. P. (2024) · Medicine International · doi:10.3892/mi.2024.137 · Cited by 37
Reijers, I. L. M., Menzies, A. M., López‐Yurda, M., Versluis, J. M., Rozeman, E. A., Saw, R. P. M., van Houdt, W. J., Kapiteijn, E., van der Veldt, A. A. M., Suijkerbuijk, K. P. M., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115141 · Cited by 35
The extent of surgery for stage III melanoma: how much is appropriate?
Franke, V., & van Akkooi, A. C. J. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30099-3 · Cited by 35
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
Hu‐Lieskovan, S., Bhaumik, S., Dhodapkar, K. M., Grivel, J., Gupta, S. V., Hanks, B. A., Janetzki, S., Kleen, T. O., Koguchi, Y., Lund, A. W., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000705 · Cited by 35
Xue, C., Li, M., Sutrisno, L., Yan, B., Zhao, Y., Hu, Y., Cai, K., Zhao, Y., Yu, S., & Luo, Z. Y. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202008732 · Cited by 35
Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma
Garutti, M., Bonin, S., Buriolla, S., Bertoli, E., Pizzichetta, M. A., Zalaudek, I., & Puglisi, F. (2021) · Cancers · doi:10.3390/cancers13081819 · Cited by 38
Guidelines for clinical evaluation of anti‐cancer drugs
Minami, H., Kiyota, N., Kimbara, S., Ando, Y., Shimokata, T., Ohtsu, A., Fuse, N., Kuboki, Y., Shimizu, T., Yamamoto, N., et al. (2021) · Cancer Science · doi:10.1111/cas.14967 · Cited by 36
Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot
Janjigian, Y. Y., Wolchok, J. D., & Ariyan, C. E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.013 · Cited by 34
Learning from the nexus of autoimmunity and cancer
Mangani, D., Yang, D., & Anderson, A. C. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.022 · Cited by 33
Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial
Coutzac, C., Bibeau, F., Abdelghani, M. B., Aparicio, T., Cohen, R., Coquan, E., Dubreuil, O., Evesque, L., Ghiringhelli, F., Kim, S. C. H., et al. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.07.008 · Cited by 35
The “-OMICS” facet of melanoma: Heterogeneity of genomic, proteomic and metabolomic biomarkers
Donnelly, D. M., Aung, P. P., & Jour, G. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.014 · Cited by 32
Han, L., Shi, H., Luo, Y., Sun, W., Li, S., Zhang, N., Jiang, X., Gong, Y. Q., & Xie, C. (2020) · Cancer Medicine · doi:10.1002/cam4.3561 · Cited by 33
Immunotherapy for the treatment of colorectal cancer
Lumish, M. A., & Cercek, A. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26357 · Cited by 34
Wölffer, M., Battke, F., Schulze, M., Feldhahn, M., Flatz, L., Martus, P., & Forschner, A. (2022) · Cancers · doi:10.3390/cancers14020302 · Cited by 35
Mac, Q. D., Sivakumar, A., Phuengkham, H., Xu, C., Bowen, J. R., Su, F., Stentz, S. Z., Sim, H., Harris, A. M., Li, T. T., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00852-y · Cited by 35
The future of targeted kinase inhibitors in melanoma
Caksa, S., Baqai, U., & Aplin, A. E. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108200 · Cited by 37
Spatial mapping of cancer tissues by OMICS technologies
Ahmed, R., Augustine, R., Valera, E., Ganguli, A., Mesaeli, N., Ahmad, I. S., Bashir, R., & Hasan, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188663 · Cited by 32
Kim, C. G., Hong, M. H., Kim, D., Lee, B. H., Kim, H., Ock, C., Kelly, G., Bang, Y. J., Kim, G., Lee, J. E., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3249 · Cited by 37
Self-citationTumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications
Bida, M., Miya, T. V., Hull, R., & Dlamini, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1497522 · Cited by 34
Kothari, A. N., White, M. G., Peacock, O., Kaur, H., Palmquist, S. M., You, N., Taggart, M. W., Salem, U. I., Overman, M. J., Kopetz, S., et al. (2022) · British journal of surgery · doi:10.1093/bjs/znac050 · Cited by 33
Eerkens, A. L., Brummel, K., Vledder, A., Paijens, S. T., Requesens, M., Loiero, D., van Rooij, N., Plat, A., Haan, F.-J., Klok, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52098-8 · Cited by 31
How I treat MSI cancers with advanced disease
Kok, M., Chalabi, M., & Haanen, J. B. A. G. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000511 · Cited by 30
Weber, J., Glutsch, V., Geissinger, E., Haug, L., Lock, J. F., Schneider, F., Kneitz, H., Goebeler, M., Schilling, B., & Gesierich, A. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18739 · Cited by 32
Toripalimab for the treatment of melanoma
Tang, B., Chi, Z., & Guo, J. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1762561 · Cited by 30
Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma
Versluis, J. M., Reijers, I. L. M., Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Wouters, M. W. J. M., Ch’ng, S., Saw, R. P. M., Scolyer, R. A., van de Wiel, B. A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.012 · Cited by 31
Metadata
- Authors
- Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., Diab, A., Wong, M. K., Royal, R., Gross, N., Weber, R., Lai, S. Y., Ehlers, R., Blando, J., Milton, D. R., Woodman, S., Kageyama, R., Wells, D. K., Hwu, P., Patel, S. P., Lucci, A., Hessel, A., Lee, J. E., Gershenwald, J., Simpson, L., Burton, E. M., Posada, L., Haydu, L., Wang, L., Zhang, S., Lazar, A. J., Hudgens, C. W., Gopalakrishnan, V., Reuben, A., Andrews, M. C., Spencer, C. N., Prieto, V., Sharma, P., Allison, J., Tetzlaff, M. T., & Wargo, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- Wargo, Jennifer A.
- ORCID
- Amaria, Rodabe N.
- Reddy, Sangeetha M.
- Tawbi, Hussein A.
- Davies, Michael A.
- Ross, Merrick I.
- Cormier, Janice N.
- Lewis, Carol
- Hwu, Wen-Jen
- Hanna, Ehab
- Diab, Adi
- Wong, Michael K.
- Gross, Neil
- Weber, Randal
- Lai, Stephen Y.
- Blando, Jorge
- Woodman, Scott
- Kageyama, Robin
- Wells, Daniel K.
- Hwu, Patrick
- Patel, Sapna P.
- Lucci, Anthony
- Lee, Jeffrey E.
- Gershenwald, Jeffrey
- Burton, Elizabeth M.
- Haydu, Lauren
- Wang, Linghua
- Zhang, Shaojun
- Lazar, Alexander J.
- Hudgens, Courtney W.
- Gopalakrishnan, Vancheswaran
- Reuben, Alexandre
- Andrews, Miles C.
- Spencer, Christine N.
- Prieto, Victor
- Sharma, Padmanee
- Allison, James
- Tetzlaff, Michael T.
- Wargo, Jennifer A.
- Venue
- Nature Medicine
- Published
- 2018-10-08
- Volume
- 24
- Issue
- 11
- Pages
- 1649-1654
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC6481682
- OpenAlex
- W2894584497
- Semantic Scholar
- 251ac2984307dc31d5a4596caa7a07c90195b1e8
- Cited by
- 835
- References
- 31
- Citations by year
- 2026: 49 · 2025: 80 · 2024: 102 · 2023: 116 · 2022: 119 · 2021: 130 · 2020: 142 · 2019: 79 · 2018: 12
- FWCI
- 34.49
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Defense
- Bristol-Myers Squibb
- Nature
- National Institutes of Health (UL1TR000371)
- University of Texas MD Anderson Cancer Center
- National Cancer Institute (T32CA009666, K08CA160692)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- melanoma, nivolumab, ipilimumab, combination immunotherapy, pathological complete response, T cell infiltration, lymphocyte infiltration, treatment-related adverse events, biomarkers
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Staging, Risk Factors, Disease-Free Survival, Neoadjuvant Therapy, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
